In the course of screening for FabG inhibitors from microbial sources, a new 24-membered ring lactone named macrolactin S, along with the known compound macrolactin B, has been isolated from the mycelium of liquid fermentation cultures of Bacillus sp. AT28. The structure of macrolactin S was determined on the basis of MS and NMR data. Macrolactin S showed a dosedependent inhibition of Staphylococcus aureus FabG, not inhibiting S. aureus FabI. Also macrolactin S inhibited the growth of S. aureus, Bacillus subtilis, and Escherichia coli.
Bacterial fatty acid synthase (FAS), which is essential for bacterial growth, consists of multiple individual enzymes, each encoded by a separate gene, in contrast to the mammalian fatty-acid synthase, which is a homodimer of single multifunctional polypeptide derived from a single gene. It is important that there is low protein sequence homology and that there are different arrangements of enzymatic-active sites between bacterial and mammalian FAS. These differences have been exploited to establish bacterial FAS as a target for antibacterial drug discovery [1ϳ3] . b -Ketoacyl-acyl carrier protein (ACP) reductase (FabG) is an essential enzyme which catalyzes the reduction of b-ketoacyl-ACP to b-hydroxyacyl-ACP in the bacterial fatty acid synthesis pathway. Since the FabG gene is well conserved in most pathogenic bacteria, it is considered to be a new potential target for broad-spectrum antibacterial agents. Epigallocatechin gallate and related polyphenol compounds have been reported to inhibit E. coli FabG [4] . Some inhibitors of other bacterial FAS are known. Triclosan and isoniazid, which are currently used antibacterial agents, have been demonstrated to act by inhibiting FabI [5, 6] . Cephalochromin and unsaturated fatty acids acting as FabI inhibitors [7, 8] , atromentin acting as a FabK inhibitor [9] , cerulenin and thiolactomycin acting as FabH/B inhibitors [3] , and platensimycin and phomallenic acid acting as FabF inhibitors [10, 11] were isolated from microorganisms. However, a FabG inhibitor of microbial origin has not been reported.
In the course of our screening for FabG inhibitors from microbial metabolites, we have isolated a new 24-membered lactone compound named macrolactin S (1) together with the known compound, macrolactin B (2) [12] , from Bacillus sp. AT28 (Fig. 1) . In this paper, we report the producing strain, fermentation, isolation, structure determination, selective inhibitory activity against FabG, and antibacterial activity of 1.
Materials
Humic acid was purchased from Tokyo Kasei (Tokyo, Japan). Soluble starch, glucose, and inorganic salts were purchased from Junsei (Tokyo, Japan). Cycloheximide, nalidixic acid, p-aminobenzoic acid, biotin, Ca-pantothenate, inositol, and thiamine-HCl were purchased from Sigma (St. Louis, MO, USA). Beef extract and yeast extract were purchased from Difco (Sparks, MD, USA). Soybean meal was purchased from Seolim Food Co. Ltd. (Namyangjoo, Korea).
The Producing Strain
The producing strain AT28 was isolated from a soil sample that was collected in 2004 near Daejeon-City, Chungcheongnam-Do, Korea. The air-dried soil (1.0 g) was suspended in 10 ml of saline and after properly diluted the suspension was spread on the humic acid agar plate (humic acid 0.1%, Na 2 HPO 4 0.05%, KCl 0.17%, MgSO 4 
Fermentation and Isolation
Fermentation was carried out in 500-ml Erlenmeyer flasks containing soluble starch 1.0%, glucose 2.0%, soybean meal 2.5%, beef extract 0.1%, yeast extract 0.4%, NaCl 0.2%, K 2 HPO 4 0.025%, and CaCO 3 0.2% (adjusted to pH 7.2 before sterilization). A piece of strain AT28 from a mature plate culture was inoculated into a 500-ml Erlenmeyer flask containing 80 ml of sterile seed liquid medium with the above composition and cultured on a rotary shaker (150 rpm) at 28°C for 3 days. For the production of 1 and 2, 5-ml portions of the seed culture were transferred into 500-ml Erlenmeyer flasks containing 100 ml of the above medium and cultivated for 7 days using the same conditions. The culture broth (3 liters) was mixed with an equal volume of Me 2 CO and then the filtrate was concentrated in vacuo. The Me 2 CO extract was extracted with EtOAc three times and the EtOAc layer was concentrated in vacuo ( Fig. 2) indicates that 2 has the same structure and absolute configuration as macrolactin B [15] .
The molecular formula of 1 was determined to be C 24 3 . The presence of this long structure and the hydroxylated methine at C-12 was confirmed by the HMBC spectrum summarized in Fig. 3 . The hydroxylated methine proton at NOEs between H-15 and H-17, H-16 and H-18, and H-17 and H-19 were observed, while an NOE between H-15 and H-18 was not observed, indicating the geometry of C-16 to be E (Fig. 3) . The stereochemistry of C-12 was also determined by NOESY data. H-12 showed strong NOEs with H-9 and H-13. Since the stereochemistry at C-13 is S, C-12 should be S (Fig. 3) . Thus, the structure of 1 was determined as shown in Fig. 1 .
Compound 1 is a derivative of macrolactin A [12] in which C-12 is hydroxylated. Macrolactin S was reported by another group earlier this year [13] . After our manuscript had been submitted to this journal, we learned about the previous publication in Natural Products Research reporting macrolactin S. It seems that the stereochemistry of 1 was the same as the previously reported macrolactin S even though there is a little discrepancy in optical rotation. Appearance of compound 1 is quite different from the reported one: a white powder vs. an yellow oil. Twenty macrolactins, a class of 24-membered lactones, such as macrolactins AϳR, 7-O-succinoylmacrolactin A, and 7-O-succinoylmacrolactin F, have been reported so far [12, 14ϳ20] . Macrolactins have been isolated from an unclassifiable deep-sea bacterium, Actinomadura sp., or Bacillus sp. Macrolactin A shows antibacterial activity, inhibits B16ϳF10 murine melanoma cancer cells in vitro, shows significant inhibition of mammalian herpes simplex viruses (types I and II) [12] , and prevents glutamate neurotoxicity in N18-RE-105 cells [16] . In addition, macrolactins FϳR, 7-O-succinoylmacrolactin A, 7-Osuccinoylmacrolactin F, and 7-O-malonylmacrolactin A have been reported to exhibit antibacterial activity against S. aureus and B. subtilis [14, 17ϳ20] .
The inhibitory activity of 1 against S. aureus FabG was evaluated with a previously described method [21] with some modifications as follows: assays contained 100 mM sodium phosphate (pH 7.4), 35 mM NaCl, 1.0% dimethyl sulfoxide, 50 mM acetoacetyl-CoA, 100 mM NADPH, and 0.39 nM S. aureus FabG in half-area, 96-well microtiter plates. Compound dissolved in dimethyl sulfoxide was added to each well. The rate of increase in the amount of NADPH in each reaction well was measured at 340 nm and 30°C by a microtiter ELISA reader using SOFTmax PRO software (Molecular Devices, California, USA). The inhibitory activity was calculated by the following formula: % of inhibitionϭ100ϫ[1Ϫ(rate in the presence of compound/rate in the untreated control)].
Compound 1 inhibited S. aureus FabG in a dose dependent manner with an IC 50 of 0.13 mM (Table 3) . Compound 2 also exhibited inhibitory effects on S. aureus FabG with similar potency. However, neither 1 nor 2 inhibited S. aureus enoyl-ACP reductase (FabI), the other reductase of bacterial FAS catalyzing the reduction of enoyl-ACP to acyl-ACP, even at 1.0 mM. This suggests that 1 and 2 selectively inhibit FabG, even though their activities are weak. The antibacterial activity of 1 against S. aureus (RN4220), B. subtilis (KCTC 1021), and Escherichia coli (KCTC 1924) was examined using microdilution broth method [14] . Compound 1 inhibited growth of E. coli and B. subtilis with an MIC of 64 mg/ml and showed weaker antibacterial activity against S. aureus with an MIC of 128 m g/ml. Compound 2 showed similar antibacterial activity. Compounds 1 and 2 showed quite different antibacterial activity from the previously reported macrolactin S which showed antibacterial activity against E. coli and S. aureus, not B. subtilis.
In summary, macrolactin S is a new 24-membered lactone isolated from a strain of Bacillus sp. AT28.
Macrolactin S selectively inhibited S. aureus FabG and also showed antibacterial activity against E. coli, B. subtilis and S. aureus. 
